Antiangiogenic activity of prostate-specific antigen

Journal of the National Cancer Institute

Volumn 91, Issue 19, 1999, Pages 1635-1640

  Fortier, Anne H ^a   Nelson, Barbara J ^a   Grella, Davida K ^a   Holaday, John W ^a  

^a ENTREMED INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0033530257     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.19.1635     Document Type: Article

References (28)

1. American Cancer Society. Facts & figures; 1999.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in rising incidence of prostate cancer. JAMA 1995;273:548-52.
3. Riegman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CB, Trapman J. Characterization of the human kallikrein locus. Genomics 1992;14:6-11.
4. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992; 75:1046-53.
5. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A, et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine [published erratum appears in Oncogene 1999;18:2411]. Oncogene 1998;17:3125-35.
6. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995;63:231-7.
7. Levesque MA, Yu H, D'Costa M, Biamandis EP. Prostate specific antigen expression by various tumors. J Clin Lab Anal 1995;9:123-8.
8. Kucera E, Kainz C, Tempfer C, Zeillinger R, Koelbl H, Sliutz G. Prostate specific antigen (PSA) in breast and ovarian cancer. Anticancer Res 1997; 17:4735-7.
9. Zarghami N, Grass L, Sauter ER, Diamandis EP. Prostate-specific antigen in serum during the menstrual cycle. Clin Chem 1997;43:1862-7.
10. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, et al. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 1995;72:728-31.
11. Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997;76:1087-94.
12. Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 1997; 75:579-88.
13. Yu H, Levesque MA, Clark GM, Diamandis EP. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 1998;4:1489-97.
14. Folkman J. What is the evidence that tumors are angiogenesis dependent? [editorial]. J Natl Cancer Inst 1990;82:4-6.
15. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
16. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
17. Sim BK Angiostatin™ and Endostatin™: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis 1998;2: 37-48.
18. Paciotti GF, Simpson B, Soltysiak KA, Myer LD, Fogler WE, Ruiz A, et al. Measurement of circulating levels of endogenous Endostatin. Proc Am Assoc Cancer Res 1999;40:66.
19. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML. et al. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 1999;59:189-97.
20. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988;107:1199-205.
21. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988;107: 1589-98.
22. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, et al. The endogeneous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994;368: 237-9.
23. 1-antichymotrypsin. Clin Chem 1991;37:9-15.
24. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 1986;46: 467-73.
25. Brawer MK, Deering RE, Brown M, Preston SD, Bingler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678-87.
26. Hanlon AL, Moore DF, Hanks GE, Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. Cancer 1998; 83:130-4.
27. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate-specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 1994;142:407-15.
28. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 1999;79:1588-93.